万维提示：
1、投稿方式：在线投稿。
2、期刊网址：
https://aasldpubs.onlinelibrary.wiley.com/journal/15273350
3、投稿网址：http://mc.manuscriptcentral.com/hep
4、官网邮箱：hepatology@aasld.org
5、官网电话：703-299-9766
6、期刊刊期：月刊，一年出版十二期。
2021年5月24日星期一
投稿须知【官网信息】
Author Guidelines
For additional tools visit Author Services – a suite of online tools for Wiley Online Library journal authors, featuring Article Tracking, e-mail Publication Alerts, and more.
AASLD Author Agreement
The National Institutes of Health Public Access Initiative
Author Guidelines
HEPATOLOGY publishes original research on the biology and diseases of the liver in both humans and experimental models.
Manuscripts should be submitted electronically at http://mc.manuscriptcentral.com/hep. Manuscripts should include a cover letter to:
David Cohen, M.D., Ph.D.
Editor, HEPATOLOGY
1001 North Fairfax Street, Ste. 400
Alexandria, VA 22314-1503
Telephone: 703-299-9766
Fax: 703-299-9676
E-mail: hepatology@aasld.org
Types of Manuscripts
The Editors will consider and publish the following:
Manuscripts describing original research must be no longer than 6,000 words (including references), abstract of 275 words, no more than 50 references, and a title with no more than 120 characters (excluding spaces). Please include all relevant portions of the Methods section, as well as all references, in the main manuscript. See Submission elements below. Manuscripts should contain no more than 8 figures and tables. Claims to novelty or priority, for findings or techniques, should be avoided. We encourage you to submit additional methodological details, nonessential figures or portions of your manuscript as supplementary material for online publication only. References cited in the main text may not be listed in the supplementary materials. The only references that may be listed in the supplement are those cited exclusively in the supplement. All submissions must adhere to the 50 reference limit.
Rapid Communications describing original research that may be groundbreaking, time-sensitive, and impactful, such as randomized, placebo-controlled clinical trials, are eligible for a rapid, thorough, and comprehensive review and publication process. Rapid Communications must be no longer than 6,000 words (including references), abstract of 275 words, no more than 50 references, and a title with no more than 120 characters (excluding spaces). The journal encourages the submission of shorter rapid communication articles, where appropriate, to communicate important advances as quickly as possible. No more than 8 figures and tables, with a maximum of 6 panels per figure. We encourage you to submit nonessential figures or portions of your manuscript as supplementary material for online publication only. Only one revised submission of each manuscript will be reviewed after an initial submission is reviewed in the rapid review process, and the revised manuscript must be submitted within one week.
Reviews of basic, clinical and translational topics should be no longer than 6,000 words (including references). The reference list need not be exhaustive. Authors interested in contributing reviews are requested to first contact the Editor or one of the Associate Editors with an outline of the proposed article. Please note that systematic reviews and meta analyses are considered to be original research, and should be submitted through the standard submission process.
Letters to the Editor may be subjected to peer review and undergo editing for clarity and brevity, and should be no longer than 500 words (including references) and include no more than 5 references and one figure. The Letters to the Editor section is not intended for the publication of original data. The titles of all letters should begin “Letter to the Editor:”
Editorials are invited by the Editor or Associate Editors and should be no longer than 1,500 words (including references) and include no more than one figure or table and 9 references in addition to the paper being discussed.
HEPATOLOGY Elsewhere should be no longer than 1,500 words (including references) and include no more than 8 references and one figure or table and are invited by an Associate Editor. The commentary should begin with a one paragraph summary of the article being discussed. Suggestions for this type of manuscript should be made to the Editor or an Associate Editor (see the Editorial Board for appropriate Associate Editors).
Special Articles are on a variety of topics and may include AASLD practice guidelines, in-depth scientific reviews, meeting reports, and comments on social policy. It's recommended that the length of each article is kept within the 6,000 words (including references) but it's also decided by the Editor on a case-by-case basis.
Master’s Perspectives are invited by the Editors and focus on major leaders in the field of hepatology who can look back on their careers and tell us about their life story and illustrate how careers in our specialty have evolved. These should be no longer than 2,500 words with two figures or tables and no references.
Introduction of the AASLD President is invited by the Editors and should be no longer than 2,500 words with one figure or table and no references.
Obituaries are invited by the Editors and should not include references.
Manuscripts that exceed the word limits listed above will be returned to the authors for shortening without a full review. Manuscripts that are redundant or contain extraneous material will be returned after a full review for shortening even if otherwise acceptable.
If the concept and idea for this study originated with anyone other than the senior or corresponding authors, please provide details in the manuscript cover letter. Specifically state in the cover letter whose idea the study was, especially if the idea came from someone who is not an author. If any of the authors were provided financial incentives or honoraria for their work on this manuscript, please provide details in the manuscript cover letter.
Submission Elements
Submissions must include the following:
Complete manuscript (title page, author information, abstract, and text) as one Microsoft Word document
Figures submitted separately in TIFF format with a resolution of 300 dpi (dots per inch) for halftones/photos, and 600 dpi for line diagrams.
No more than 8 figures and tables, with a maximum of 6 panels per figure. We encourage you to submit non-essential figures or portions of your manuscript as supplementary material for online publication only
Any material that could constitute prior or concurrent publication of similar data by any of the authors, including symposium proceedings, book chapters, invited papers, and the like
The names of reviewers whose expertise qualifies them to review the work
A description of any commercial affiliation or consultancy of an author that could be construed as a conflict of interest (this information will be kept confidential unless the Editor recommends disclosure in a footnote if an appearance of a conflict is perceived)
An author agreement signed by every contributing author. It is assumed, however, that the corresponding author speaks for his or her coauthors and certifies that all listed authors participated meaningfully in the study and that they have seen and approved the final manuscript.
Editorial formatting (use of italics, superscripts, Greek letter, etc.) should be consistent. Typographical formatting (column widths, type styles, etc.) should not be used. Text should be flush left; paragraphs should not be indented and should be separated by two hard returns. Do not use hard returns within paragraphs. Do not use the program's indenting or margin-setting features; these will be added during typesetting.
Submissions may include the names of any reviewers the authors wish to exclude along with the reason for exclusion for the Editors to consider.
Requests to exclude an Associate Editor can only be considered if a clear conflict of interest is explained in the cover letter.
Manuscript Organization
All elements of a manuscript should be double-spaced, and all pages must be numbered in the upper right corner, starting with the title page. Manuscripts describing original research should contain, in this order, the following elements:
Title Page
Title. No more than 120 characters, not including spaces between words. The use of acronyms and abbreviations should be avoided. The species used for work with experimental animals must be indicated in the title.
Author Names. The full name, e-mail, and institutional affiliation of all authors must be included. In a multi-authored work involving more than a single institution, indicate individual affiliation by means of a superscript Arabic number. Indicate a change of address similarly.
Keywords. Five keywords that do not appear in the title itself.
Footnote Page
Contact Information. Name, address, telephone number, fax number, and e-mail address for the corresponding author.
List of Abbreviations. Include the expansions and list in the order of their mention in the paper.
Financial Support. List grants and other financial support.
Abstract
Write as continuous text organized as background and rationale for the study, main results, and conclusions. Acronyms and abbreviations must be defined in the abstract to allow the abstract to stand alone. Please refrain from using statements of priority (such as “This is the first study to show…”). Do not exceed 275 words. The abstract should be structured into three sections, headed: Background & Aims, Approach & Results and Conclusions.
Introductory Statement
Do not include a heading. Provide the minimum background information that will orient the general reader.
Experimental Procedures
Provide a level of detail such that another investigator could repeat the work; for methods that are used without significant modification, citation of the original work will suffice.
Human Subjects. For reports of research using human subjects, provide assurance that (a) informed consent in writing was obtained from each patient and (b) the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the appropriate institutional review committee. This assurance must be included in the main text of the manuscript rather than supplementary material. Refer to individual patients by number, not by initials. HEPATOLOGY will only accept papers for review from liver transplant centers that explicitly state that no donor organs were obtained from executed prisoners or other institutionalized persons. Papers without such explicit statements will be returned without review.
Clinical Trials. HEPATOLOGY uses the definition of clinical trials promulgated by the International Committee of Medical Journal Editors (ICMJE, http://www.icmje.org): Any research project that prospectively assigns people or a group of people to an intervention, with or without concurrent comparison or control groups, to study the relationship between a health-related intervention and a health outcome. Health-related interventions are those used to modify a biomedical or health-related outcome; examples include drugs, surgical procedures, devices, behavioral treatments, educational programs, dietary interventions, quality improvement interventions, and process-of-care changes. Health outcomes are any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events.
Randomized controlled trials should be presented according to the CONSORT guidelines (JAMA 2001;285:1987-1991 or http://www.consort-statement.org). Authors must provide the CONSORT checklist (found at http://mc.manuscriptcentral.com/hep, under Instructions and Forms) with a diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. Manuscripts that fail to comply with CONSORT guidelines or do not include the CONSORT checklist at the time of submission will not be reviewed for publication. Manuscripts describing randomized control trials should also include in the text of the manuscript the following information: The identity of those who designed the protocol and analyzed the data; A statement indicating that at least one author had access to all of the data and can vouch for the integrity of the data analyses; Disclosure of any funding sources and their role, if any, in the writing of the manuscript or the decision to submit it for publication; Statements of role, if any, of medical writer or editor.
Authors of manuscripts reporting clinical trials must submit a proof of institutional review board approval from all participating centers, the original approved protocol, patient information sheet and statistical analysis plan, and all subsequent amendments to either document. All these documents must be in English language. If the manuscript is accepted, the protocol and statistical analysis plan will be published as an online supplement.
HEPATOLOGY endorses the recommendations of the ICMJE regarding the registration of clinical trials. Trials must be registered in a registry that is a primary register of the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) or in ClinicalTrials.gov, which is a data provider to the WHO ICTRP. The trial registration number must be included on the title page of any manuscript reporting a registered clinical trial. Trials should be registered by the time of first participant consent.
Animal Experimentation. In studies involving animal experimentation, provide assurance that all animals received humane care according to the criteria outlined in the “Guide for the Care and Use of Laboratory Animals.” This assurance must be included in the main text of the manuscript rather than supplementary material. Manuscripts that use mice and other in vivo experimental models should include the following information:
Sex and age of mice (or other in vivo experimental models) for all the experiments;
The genetic background(s) of the mice or other experimental in vivo models;
For transgenic or genetic mouse models, whether the controls were sibling littermates or were purchased separately (if purchased separately, were the animals cohoused to minimize potential microbiome effects);
Specifics of the animal diet composition;
Whether mice were fasted (and for how long) or not before a challenge or assessment is carried out;
Type of bedding, caging system, and enrichment used for housing the mice; and
If interventions were done, were they done during the light or dark cycle.
Nomenclature: Mouse strains and cell lines should be italicized, and superscript if they are knockout or transgenic strains, e.g., ob/ob(KO), p53+/+, p53-/-.
Statistical methods used should be outlined, in addition to if sex was considered a factor in the statistical analysis.
Data Deposition. HEPATOLOGY supports the use of databases to aggregate published data for the use of the wider scientific community, and endorses the policies first adopted by the Science journals regarding data deposition (http://www.sciencemag.org/authors/science-journals-editorial-policies#data-deposition). Prior to publication, data sets (including microarray data, protein or DNA sequences) must be deposited in an approved database and an accession number or a specific access address must be included in the published paper. This information need not accompany the initially submitted manuscript but must be available for inclusion in the final publication. Accession numbers appear as footnotes to the text or in the relevant figure legend. We encourage compliance with MIBBI guidelines (Minimum Information for Biological and Biomedical Investigations).
DNA and protein sequences: Approved databases are GenBank or other members of the International Nucleotide Sequence Database Collaboration (EMBL or DDBJ) and SWISS-PROT.
Microarray data: Data should be presented in MIAME-compliant standard format. Approved databases are Gene Expression Omnibus and ArrayExpress.
It is understood that authors publishing in HEPATOLOGY will make cloned DNA, hybridomas, mutant animals, and other resources available to qualified investigators. Raw data submitted with a manuscript may only be electronically published and available to HEPATOLOGY readers at the Journal’s Web site.
Cell Lines. Experiments utilizing cell lines should wherever possible be replicated in more than one cell line. When primary cell lines are utilized, at least three separate batches should be used. Whenever cell lines are used, authors should include the following information:
The source of the cells used: For established cell lines, this should include a reference to the published article that first described the cell line, or the cell line repository or company the cell line was obtained from, the catalogue number, and whether the cell line was obtained directly from the repository/company or from another laboratory
Cell line authentication is recommended – e.g., by karyotyping, isozyme analysis, or short tandem repeats (STR) analysis – and may be required during peer review or after publication. Where cell line authentication is carried out, this must be described in the methods section. Authors should be able to provide the test results upon request. Mycoplasma contamination testing status must also be reported.
In order to minimize the use of cross-contaminated or misidentified cell lines, authors should check established cell lines using the ICLAC Database of Cross-contaminated or Misidentified Cell Lines (https://iclac.org/databases/cross-contaminations/)
It has recently become clear that a number of commonly used HCC cell lines have become cross-contaminated with other cells, including HeLa, the oldest and most widely used human cell line, derived from a cervical carcinoma. For further details, please see the Editorial in the Journal of Hepatology (https://www.journal-of-hepatology.eu/article/S0168-8278(17)32206-7/fulltext). For this reason, HEPATOLOGY will no longer consider BEL7402, SMMC7721, MHCC97L, BEL7404, QGY7701, QGY7703, QSG7701 and SKHEP1 as HCC cell lines, unless authors are authors are able to demonstrate their origin through STR, hepatic gene expression and specific gene mutations.
Antibodies. A table listing any antibodies used (including for immunohistochemistry, immunocytochemistry or Western blots) should be included in the supplementary data, and should include the catalog number (and/or clone number) or primary citation for each antibody, appropriate positive and negative controls, validation of each antibody and any necessary references.
Manufacturers. Include the names and locations (city and state or country) of manufacturers when mentioning proprietary drugs, tools, instruments, software, etc.
Statistics. HEPATOLOGY endorses the guidelines on the reporting of statistics issued by the ICMJE (http://www.icmje.org/recommendations/browse/manuscript-preparation/preparing-for-submission.html#d): “Describe statistical methods with enough detail to enable a knowledgeable reader with access to the original data to judge its appropriateness for the study and to verify the reported results. When possible, quantify findings and present them with appropriate indicators of measurement error or uncertainty (such as confidence intervals). Avoid relying solely on statistical hypothesis testing, such as P values, which fail to convey important information about effect size and precision of estimates. References for the design of the study and statistical methods should be to standard works when possible (with pages stated). Define statistical terms, abbreviations, and most symbols. Specify the statistical software package(s) and versions used. Distinguish prespecified from exploratory analyses, including subgroup analyses.“ In addition, the following specific guidance, adopted from the Journal of Hepatology, should be followed:
Complex analyses should be performed with the assistance of a qualified statistician and should be extensively described in the supplemental material to ensure reproducibility of the results together with an access to the primary results in public database or upon request. Unqualified use of such analyses is strongly discouraged.
The underlying assumptions of the statistical methods used should be tested to ensure that the assumptions are fulfilled.
For small data sets and if variable distributions are non-normal, distribution free (non-parametric) statistical methods should be used. The actual p values – whether significant or not – should always be presented (not n.s.).
Confidence intervals convey more information than p values and should be presented whenever possible. Continuous variables can always be summarized using the median and range which are therefore preferred. Only in the infrequent case of a normal distribution are the mean and standard deviation (SD) useful.
Complex analyses (including Cox and logistic regression analysis) should be presented in sufficient detail: i.e., variable scoring, regression coefficients, standard errors and any constants. Odds-ratios or relative risks are not sufficient documentation of such analyses.
The handling of any missing values in the data should be clearly specified. The number of statistical tests performed should be kept at a minimum to reduce spurious positive results. Explorative (hypothesis generating) analyses without confirmation using independent data are discouraged.
Figures showing individual observations e.g., scatter plots are encouraged. Histograms may also be useful. Tables should indicate the number of observations on which each result is being based. A statistical review of the paper will be sought from an expert where necessary.
Results and Discussion
These two sections must be separate. Present the major findings of the study in graphic form if practicable. Do not illustrate minor details if their message is conveyed adequately by simple descriptive text. Mention all tables and figures. In the discussion, concisely present the implications of the new findings for the field as a whole, minimizing reiteration of the results, avoiding repetition of material in the introduction, and keeping a close focus on the specific topic of the paper.
Reporting Guidelines. HEPATOLOGY endorses the use of appropriate reporting guidelines when writing any research manuscript. Reporting guidelines can be found on the EQUATOR Network, which also gives general information on how to choose the correct guideline and why guidelines are important. At the minimum, your article should report the content addressed by each item of the identified checklist or state that the item was not considered in the study (for example, if you did not use blinding, your article should say so). Meeting these basic reporting requirements will greatly improve the value of your manuscript, may facilitate/enhance the peer review process, and may enhance its chances for eventual publication. Authors may use the following free online tool to assist in selecting the correct guidelines for their research: https://www.penelope.ai/equator-wizard.
……
更多详情：
https://aasldpubs.onlinelibrary.wiley.com/hub/journal/15273350/about/author-guidelines
